Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | SMPD3 | Q9NY59 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16376282 | 0.82 | SMN1; SMN2 (0.37) | ALDH1A1SMN1; SMN2KMT2AIRAK4CYP1A2 | |
| SCHEMBL16376281 | 0.81 | SMN1; SMN2 (0.36) | ALDH1A1SMN1; SMN2KMT2ACYP1A2SMPD3 | |
| SCHEMBL16376269 | 0.80 | CYP1A2 (0.33) | ALDH1A1SMN1; SMN2CYP1A2SMPD3LMNA | |
| SCHEMBL28529693 | 0.73 | SMN1; SMN2 (0.44) | ALDH1A1SMN1; SMN2KMT2AKDM4E | |
| SCHEMBL22445908 | 0.72 | APOBEC3A (0.41) | ALDH1A1ALOX15SMN1; SMN2KMT2AKDM4E | |
| SCHEMBL31497245 | 0.72 | SMPD3 (0.40) | ALDH1A1NPC1RAB9ASMN1; SMN2CYP1A2 | |
| SCHEMBL28524393 | 0.71 | APOBEC3A (0.41) | ALDH1A1ALOX15RAB9ASMN1; SMN2KMT2A | |
| SCHEMBL28527557 | 0.68 | KCNH2 (0.41) | ALDH1A1NPC1RAB9AKMT2AKDM4E | |
| SCHEMBL31001828 | 0.67 | DYRK1A (0.47) | NPC1RAB9AKMT2AKDM4ELMNA | |
| SCHEMBL23254467 | 0.64 | KCNH2 (0.38) | ALDH1A1NPSR1KMT2AKDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240067646-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | HOFFMANN-LA ROCHE INC. | 2024-02-29 | — | — | US | disclosed |
| US-11753407-B2 | Compounds for treating spinal muscular atrophy | PTC THERAPEUTICS, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-20180105526-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC THERAPEUTICS INC (US) | 2018-04-19 | — | — | US | disclosed |
| US-9586955-B2 | Compounds for treating spinal muscular atrophy | PTC THERAPEUTICS, INC. (US) | 2017-03-07 | — | — | US | disclosed |
| US-20150005289-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | HOFFMANN-LA ROCHE INC. | 2015-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240067646-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | SMN1; SMN2, CPT1B, GYS1 | ALDH1A1 1088/4885NPC1 1156/4885TP53 4877/4885 |
| US-20150005289-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | SMN1; SMN2, CPT1B, GYS1 | ALDH1A1 1461/4885NPC1 975/4885TP53 4855/4885 |
| US-20180105526-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | SMN1; SMN2, CPT1B, GYS1 | ALDH1A1 1461/4885NPC1 975/4885TP53 4855/4885 |
| US-11753407-B2 | Compounds for treating spinal muscular atrophy | SMN1; SMN2, CPT1B, GYS1 | ALDH1A1 1651/4885NPC1 2355/4885TP53 4851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.